---
layout: post
title: "M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry; Reopening of the Comment Period"
date: 2026-02-04 21:49:16 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-17292
original_published: 2025-09-09 00:00:00 +0000
significance: 8.00
---

# M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry; Reopening of the Comment Period

**Published:** February 04, 2026 21:49 UTC
**Source:** Federal Register
**Original Published:** September 09, 2025 00:00 UTC
**Document Number:** 2025-17292

## Summary

The Food and Drug Administration (FDA or the Agency) is reopening the comment period for the draft guidance announced in the notice entitled "M13B Bioequivalence for Immediate-Release Solid Oral Dosage Forms: Additional Strengths Biowaiver; International Council for Harmonisation; Draft Guidance for Industry," published in the Federal Register of June 2, 2025. The Agency is taking this action to allow interested persons additional time to submit comments.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/09/09/2025-17292/m13b-bioequivalence-for-immediate-release-solid-oral-dosage-forms-additional-strengths-biowaiver)
- API: https://www.federalregister.gov/api/v1/documents/2025-17292

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
